Here is the release in full with relevant products listed
Medicinal cannabis products that meet the minimum quality standard
The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 (the Regulations) set the minimum quality standard that medicinal cannabis products and ingredients must meet before they can be supplied in New Zealand. Importers, manufacturers, and suppliers must apply for assessment and provide evidence to the Medicinal Cannabis Agency to verify that their products meet the minimum quality standard.
Rua Puāwai THC26 has been verified as meeting the minimum quality standard.
Rua Puāwai THC18 White Widow has been verified as meeting the minimum quality standard.
More information on the products can be found on the Ministry of Health website.
…/…
11 July 2024: New medicinal cannabis products have been verified as meeting the minimum quality standard – Read more.
Generally, medicinal cannabis products are only available, on prescription, if they have:
- been assessed by the Medicinal Cannabis Agency as meeting the minimum quality standard under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, or
- obtained consent for distribution under the Medicines Act 1981 (approved and provisionally approved medicines)
Any doctor can prescribe a product listed here. A specialist recommendation and Ministerial approval are not required. For more information on a particular product, please contact the listed product supplier or manufacturer.
Medicinal cannabis products that meet the minimum quality standard under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019
The minimum quality standard is used to verify medicinal cannabis products which have been derived from the Cannabis plant. Synthetic CBD and THC products are unable to be verified to meet the minimum quality standard as they are not derived from the Cannabis plant.
Products that are listed as having been verified as meeting the minimum quality standard are unapproved medicines – there has been no assessment of their safety or efficacy. Being listed here does not guarantee that these products are currently available in New Zealand. For the most up-to-date information on product availability contact the licence holder.
Some verified products may not be listed here at the request of the licence holder.
Dosage Products – Prescription Medicine
The products listed in the following tables are categorised by their verified dosage form. The products have been verified as meeting the testing requirements and microbiological contamination limits applicable to the dosage form as listed.
Oral Liquids
| Product Name | Active Ingredients | Pack Sizes (mL) | Administration notes | Licence holder |
|---|---|---|---|---|
| Helius CBD25 Full Spectrum | Total CBD (CBD+CBDA) 25 mg/mL | 30 | Oral, withdraw prescribed dose using provided dropper and dispense into mouth | Helius Therapeutics Limited |
| Helius CBD100 Full Spectrum | Total CBD (CBD+CBDA) 100 mg/mL | 30 | Oral, withdraw prescribed dose using provided dropper and dispense into mouth | Helius Therapeutics Limited |
| Tilray P Oral Solution CBD 100 | Total CBD (CBD+CBDA) 106.4 mg/g (100 mg/mL) | 25, 40 | Oral, 1 mL oral syringe with 0.1 mL volume markings | CDC Pharmaceuticals Ltd |
| Tilray P Oral Solution CBD 25 | Total CBD (CBD+CBDA) 26.6 mg/g (25 mg/mL) | 40 | Oral, 1 mL oral syringe with 0.1mL volume markings | CDC Pharmaceuticals Ltd |
| ANTG Elan Oil [CBD100] | Total CBD (CBD+CBDA) 100 mg/mL | 30 | Oral via 1.5 mL LDPE standard syringe | MW Pharma Limited t/a NUBU Pharmaceuticals |
Sublingual Solutions
| Product Name | Active Ingredients | Pack Sizes (mL) | Administration notes | Licence holder |
|---|---|---|---|---|
| Helius SubDrops® CBD100 | Total CBD (CBD+CBDA) 100 mg/mL | 30 | Sublingual, 1 mL dropper with 0.25 mL volume markings | Helius Therapeutics Limited |
| Helius SubDrops® CBD25 | Total CBD (CBD+CBDA) 25 mg/mL | 30 | Sublingual, 1 mL dropper with 0.25 mL volume markings | Helius Therapeutics Limited |
| Eqalis CBD120 | Total CBD (CBD+CBDA) = 120 mg/mL
Total THC (Δ9-THC+THCA) < 2.4 mg/mL |
30 | Sublingual, 1 mL dropper with 0.25 mL volume markings | Eqalis Pharmaceuticals Limited |
| Eqalis CBD30 | Total CBD (CBD+CBDA) = 30 mg/mL
Total THC (Δ9-THC+THCA) < 0.6 mg/mL |
30 | Sublingual, 1 mL dropper with 0.25 mL volume markings | Eqalis Pharmaceuticals Limited |
Dosage Products – Controlled Drug B1
Oral Liquids
| Product Name | Active Ingredients | Pack Sizes (mL) | Administration notes | Licence holder |
|---|---|---|---|---|
| evalaCann THC ≤1 mg: CBD 20 mg | Total THC (THC+THCA) ≤1 mg
Total CBD (CBD+CBDA) 20 mg |
30 | Oral, 1 mL or 1.5 mL oral; syringe with 0.1 mL volume markings | Cannasouth Bioscience Ltd |
| evalaCann THC 10 mg: CBD 15 mg | Total THC (THC+THCA) 10 mg
Total CBD (CBD+CBDA) 15 mg |
30 | Oral, 1 mL or 1.5 mL oral; syringe with 0.1 mL volume markings | Cannasouth Bioscience Ltd |
| evalaCann THC 10 mg: CBD ≤1 mg | Total THC (THC+THCA) 10 mg
Total CBD (CBD+CBDA) ≤1 mg |
30 | Oral, 1 mL or 1.5 mL oral; syringe with 0.1 mL volume markings | Cannasouth Bioscience Ltd |
| Helius THC25 Full Spectrum | Total THC (THC+THCA) 25 mg/mL
Total CBD (CBD+CBDA) ≤2 mg/mL |
30 | Oral, withdraw prescribed dose with provided oral syringe and dispense into mouth. Provided with 1 mL oral syringe with 0.1mL markings | Helius Therapeutics Limited |
| Helius THC10:CBD10 Full Spectrum | Total THC (THC+THCA) 10 mg/mL
Total CBD (CBD+CBDA) 10 mg/mL |
30 | Oral, withdraw prescribed dose with provided oral syringe and dispense into mouth. Provided with 1 mL oral syringe with 0.1mL markings | Helius Therapeutics Limited |
| Tilray FS oral Solution THC 25 | Total THC (THC+THCA) 26.44 mg / g (25 mg/ mL) | 40 | Oral, 1 mL oral syringe with 0.1 mL volume markings | CDC Pharmaceuticals Ltd |
| Tilray FS Oral Solution THC 10 CBD 10 | Total THC (THC+THCA) 10.5 mg/g (10 mg/mL)
Total CBD (CBD+CBDA) 10.5 mg/g (10 mg/mL) |
40 | Oral, 1 mL oral syringe with 0.1 mL volume markings | CDC Pharmaceuticals Ltd |
| Tilray FS Oral Solution THC 5: CBD 20 | Total THC (THC+THCA) 5.3 mg/g (5 mg/mL)
Total CBD (CBD+CBDA) 21.3 mg/g (20 mg/mL) |
40 | Oral, 1 mL oral syringe with 0.1 mL volume markings | CDC Pharmaceuticals Ltd |
| ANTG Rocky Oil [FS THC30] | Total THC (THC+THCA) 30 mg/mLTotal CBD (CBD+CBDA) < 1 mg/mL | 50 | Oral via 1.5 mL LDPE standard syringe | MW Pharma Limited t/a NUBU Pharmaceuticals |
| ANTG Luna Oil [FS THC10 CBD10] | Total THC (THC+THCA) 10 mg/mL Total CBD (CBD+CBDA) 10 mg/mL |
50 | Oral via 1.5 mL LDPE standard syringe | MW Pharma Limited t/a NUBU Pharmaceuticals |
| ANTG Eve Oil [FS THC2 CBD50] | Total THC (THC+THCA) ≤ 2 mg/mL Total CBD (CBD+CBDA) 50 mg/mL |
50 | Oral via 1.5 mL LDPE standard syringe | MW Pharma Limited t/a NUBU Pharmaceuticals |
Dried Products- Controlled Drug C1
The products listed in the following tables are categorised by their verified administration route. The products have been verified as meeting the microbiological contamination limits for the administration route as listed.
Dried cannabis flower for inhalation via a vaporiser
| Product Name | Active Ingredients | Pack Sizes (g) | Administration notes | Licence holder |
|---|---|---|---|---|
| KIKUYA Dune | Total THC (THC+THCA) 190 mg/g (19% w/w) Total CBD (CBD+CBDA) ≤10 mg/g (≤1%w/w) | 10 | Inhalation via vaporiser | MW Pharma Limited t/a NUBU Pharmaceuticals |
| KIKUYA Arroyo | Total THC (THC+THCA) 200 mg/g (20% w/w) Total CBD (CBD+CBDA) ≤10 mg/g (≤1% w/w) | 10 | Inhalation via vaporiser | MW Pharma Limited t/a NUBU Pharmaceuticals |
| Tilray Whole Flower Dried Cannabis THC 22 | Total THC (THC+THCA) 22 % w/w Total CBD (CBD+CBDA) ≤1% w/w | 15 | Inhalation via vaporiser | CDC Pharmaceuticals Ltd |
| Equiposa | Total THC (THC+THCA) 9.0 % w/w Total CBD (CBD+CBDA) 8.3 % w/w | 15 | Inhalation via vaporiser | Indica Industries Ltd |
| Luminarium | Total THC (THC+THCA) 22.5 % w/w Total CBD (CBD+CBDA) ≤1 % w/w | 15 | Inhalation via vaporiser | Indica Industries Ltd |
| Sedaprem | Total THC (THC+THCA) 21.3 % w/w Total CBD (CBD+CBDA) ≤1% w/w | 15 | Inhalation via vaporiser | Indica Industries Ltd |
| KIKUYA Peak | Total THC (THC+THCA) 255 mg/g (25.5 % w/w) Total CBD (CBD+CBDA) ≤10 mg/g (≤1% w/w) | 10 | Inhalation via vaporiser | MW Pharma Limited t/a NUBU Pharmaceuticals |
| Helius DK Dusk THC25 | Total THC (THC+THCA) 25 % w/w Total CBD (CBD+CBDA) ≤ 1 % w/w |
10 | Inhalation via vaporiser | Helius Therapeutics Limited |
| Helius DK Dawn THC22 | Total THC (THC+THCA) 22 % w/w Total CBD (CBD+CBDA) ≤ 1 % w/w |
10 | Inhalation via vaporiser | Helius Therapeutics Limited |
| Tilray Whole Flower Dried Cannabis THC 25 | Total THC (THC+THCA) 25 % w/w Total CBD (CBD+CBDA) ≤1% w/w | 15 | Inhalation via vaporiser | CDC Pharmaceuticals Ltd |
| KIKUYA Cove | Total THC (THC+THCA) 190 mg/g (19.0 % w/w) Total CBD (CBD+CBDA) ≤10 mg/g (≤1% w/w) | 10 | Inhalation via vaporiser | MW Pharma Limited t/a NUBU Pharmaceuticals |
| Rua Puāwai THC26 | Total THC (THC + THCA) 26 % w/w
Total CBD (CBD + CBDA) ≤ 1 % w/w |
10 | Inhalation via vaporiser | Rua Bioscience Limited |
| Rua Puāwai THC18 White Widow | Total THC (THC + THCA) 18 % w/w
Total CBD (CBD + CBDA) < 1 % w/w |
10 | Inhalation via vaporiser | Rua Bioscience Limited |
Dried cannabis flower for preparation of tea for oral consumption
Note: This product does not meet the minimum quality standard for inhalation
| Product Name | Active Ingredients | Pack Sizes (g) | Administration notes | Licence holder |
|---|---|---|---|---|
| ANTG Eve | Total THC (THC+THCA) 10 mg/g (˂ 1% w/w)
Total CBD (CBD+CBDA) 125 mg/g (12.5% w/w) |
10 | Tea preparation for oral consumption. View tea preparation instructions.
|
MW Pharma Limited t/a NUBU Pharmaceuticals |
| ANTG Mariposa | Total THC (THC+THCA) 135 mg/g (13.5% w/w)
Total CBD (CBD+CBDA) <10 mg/g (<1% w/w) |
10 | Tea preparation for oral consumption. View tea preparation instructions
|
MW Pharma Limited t/a NUBU Pharmaceuticals |
| ANTG Rocky | Total THC (THC+THCA) 250 mg/g (25% w/w)
Total CBD (CBD+CBDA) <10 mg/g (<1% w/w) |
10 | Tea preparation for oral consumption. View tea preparation instructions
|
MW Pharma Limited t/a NUBU Pharmaceuticals |
| ANTG Solace | Total THC (THC+THCA): 200 mg/g (20% w/w)
Total CBD (CBD+CBDA): <10 mg/g (<1% w/w) |
10 | Tea preparation for oral consumption. View tea preparation instructions |
MW Pharma Limited t/a NUBU Pharmaceuticals |
| Medleaf Medium THC Shishkaberry | Total THC (THC+THCA): 152.5 mg/g (15.25% w/w)
Total CBD (CBD+CBDA): <5 mg/g (<0.5% w/w) |
35 | Tea preparation for oral consumption. View tea preparation instructions |
JC logistics t/a Medleaf Therapeutics |
| Medleaf Zour Apple | Total THC (THC+THCA) 21% w/w
Total CBD (CBD+CBDA) <1%w/w |
30 g | Tea preparation for oral consumption. View tea preparation instructions |
JC logistics t/a Medleaf Therapeutics |
| Medleaf GG#4 | Total THC (THC+THCA) 24% w/w
Total CBD (CBD+CBDA) <1%w/w |
30 g | Tea preparation for oral consumption. View tea preparation instructions |
JC logistics t/a Medleaf Therapeutics |
| Medleaf LL Kush | Total THC (THC+THCA) 23% w/w
Total CBD (CBD+CBDA) <1%w/w |
30 g | Tea preparation for oral consumption. View tea preparation instructions |
JC logistics t/a Medleaf Therapeutics |
| Cumulus T17 | Total THC (THC+THCA) = 17% w/w
Total CBD (CBD + CBDA) <2% w/w |
10 | Tea preparation for oral consumption. View tea preparation instructions |
Cannasouth Bioscience Limited |
| Symetis T17 B52 | Total THC (THC+THCA) = 17% w/w
Total CBD (CBD + CBDA) <2% w/w |
10 | Tea preparation for oral consumption. View tea preparation instructions |
Cannasouth Bioscience Limited |
| Medleaf Orange Kush C | Total THC (THC+THCA) 21% w/w
Total CBD (CBD+CBDA) <1%w/w |
30 | Tea preparation for oral consumption. View tea preparation instructions |
JC logistics t/a Medleaf Therapeutics |
Products with consent for distribution (approved and provisionally approved) under the Medicines Act 1981
Approved and provisionally approved medicines have been assessed by Medsafe and have demonstrated that they meet New Zealand and internationally recognised standards for quality, safety and efficacy. Approved and provisionally approved medicines are not required to be assessed against the minimum quality standard.
| Product Name | Active Ingredients | Dose Form | Prescribing information | Information for consumers | Sponsor |
|---|---|---|---|---|---|
| Sativex oromucosal spray | CBD 25 mg/mL equivalent to Cannabis sativa extract 35 mg–42 mg THC 27 mg/mL equivalent to Cannabis sativa extract 38 mg–44 mg |
Oromucosal spray | Sativex data sheet (191 KB) | Sativex consumer medicine information (PDF, 210 KB) | Chiesi New Zealand Limited t/a Emerge Health |
| Epidyolex oral solution |
Cannabidiol 100 mg/mL | Oral solution | Epidyolex data sheet (PDF, 424 KB) | Epidyolex consumer medicine information (PDF, 347 KB) | Chiesi New Zealand Limited t/a Emerge Health |
Tea preparation instructions
- Bring 500 ml (0.5 litres) of water to the boil in a covered vessel
- Granulate product (using a grinder is easiest) into fine pieces
- Add 0.5 gram of product to vessel
- Turn down the heat and simmer the tea for 15 minutes with the lid on the vessel
- Remove the covered vessel from the heat and strain the tea
- Store the leftover tea in a thermos if you are to drink more of it on the same day
After preparation – as described above – add a sachet of coffee creamer powder to the warm tea. This prevents the active ingredients in the tea from sticking to the inside of the teapot or mug after cooling.
